- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05886738
Investigating the Effect of Short-term Fasting on T Cell Metabolism, Function, and Phenotype in Obesity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recruitment and Eligibility:
This is a two-group pre-post study which has been approved by the UBC Clinical Research Ethics Board (H22-03605). Participants will be recruited from the community and the UBC Okanagan campus with posters and social media posts. Additionally, an email invitation will be sent to participants from past studies that have indicated on their previous Consent Forms that they agree to be contacted for future research studies. The investigators will aim to recruit equal numbers of males and females in each group. Interested volunteers will be initially screened via a standardized phone call to determine if they meet the eligibility criteria. If the eligibility criteria are met, they will be invited to participate in the study, researchers will discuss the study details with the potential participant, and participants will be sent the Consent Form to review and sign if they consent to participate. This study will compare the responses of individuals with obesity to individuals that are lean. Lean individuals will be included if they have a body mass index (BMI) between 18.5 and 24.9 kg/m2 and a waist circumference < 88 cm (females) or < 102 cm (males). Individuals with obesity will be included if they have a BMI of > 30 kg/m2 or a waist circumference > 88 cm (females) or > 102 cm (males). Lean individuals will be age- and sex-matched to individuals with obesity, and individuals in both groups will be included if they are 19-69 years of age and are physically inactive. This will be defined as accumulating < 150 minutes of moderate-to-vigorous physical activity per week or participating in moderate-to-vigorous physical activity < 3 days per week. Additionally, all participants must be able to read and understand English in order to complete the study diet logs. Interested volunteers will be excluded if they have a diagnosed autoimmune or inflammatory disease, have had a cancer diagnosis and/or treatment within the last 5 years, diagnosed type 1 or 2 diabetes, or a history of cardiovascular events (i.e., heart attack, stroke), and/or are currently pregnant. Additionally, interested volunteers will be excluded if they take glucose-lowering or thyroid medications, or if they currently smoke cigarettes or cannot refrain from smoking/using cannabis for the duration of the study. Finally, individuals that actively take ketone supplements, practice intermittent fasting with regular periods of fasting > 24 hours, follow a ketogenic diet, or are actively trying to lose or gain weight (> 4 kg weight loss or gain in last month) will be excluded from the study.
Visits Summary This study will involve a total of 3 visits across 48 hours during which participants will be in the laboratory for a total of 5 hours (study design pictured in Figure 1). Participants will be fasted during the 48 hours, and upon arrival to their final visit will be provided with a meal.
Prior to coming in to the lab the investigators will have already obtained informed consent, and the investigators will have participants log all of the food and drinks that they consume in a diary for the 3 days before their first visit. They will bring this 3-day food log with them to their first visit to the lab. Additionally, the investigators will ask participants not to consume any alcohol or participate in any exercise the day before their first visit.
Visit 1: 1 hour On the first visit, participants will consume a standardized breakfast (meal replacement drink). Once they have consumed this meal, their fast will begin and they will arrive at the laboratory 4 hours later. Researchers will measure height, body weight, waist circumference, and blood pressure. A blood sample will be obtained from the antecubital vein by a trained phlebotomist (Hashim Islam, PhD; Helena Neudorf, PhD student) using a standard 21-gauge needle. Approximately 20 ml of blood will be drawn into EDTA tubes. Following this, the investigators will measure resting metabolic rate (RMR). To do this, participants will rest lying down in a supine position and connected to a metabolic cart (Parvo Medics TrueOne 2400) with which their expired air will be collected and analyzed for 30 minutes. Participants will be instructed not to consume any food or beverages other than water or calorie- and sugar-free beverages (provided by the researchers) if they wish, or partake in any moderate-to-vigorous physical activity for the duration of their fast.
Visit 2: 30 minutes Participants will arrive for their second visit 24 hours following their first visit. During this visit, 20 ml of blood will be obtained by a trained phlebotomist in the same manner as the first visit, and participants will again be offered calorie- and sugar-free beverages if they wish.
Visit 3: 3.5 hours Participants will arrive for their third and final visit having fasted for 48 hours. RMR and a blood sample (20 ml) will be collected, and participants will be provided with the same meal replacement drink a standardized breakfast to end their fast. Participants will remain in the laboratory for the next 3 hours, during which the investigators will collect RMR on the second half of every hour in the same manner as the first visit. At the end of the 3 hours, the investigators will collect a final blood sample (20 ml) will be collected.
Statistical Analyses Changes in all variables over time will be compared between the two groups using a linear mixed effects model with subject included as a random factor and group, time, and baseline measures will be included as fixed factors.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- are 19-69 years of age, and
- have body mass index (BMI) of between 18.5 and 24.9 kg/m2 and a waist circumference of less than 88 cm (females) or 102 cm (males), or
- have a BMI over 30 kg/m2 or a waist circumference of more than 88 cm (females) or 102 cm (males)
- can read and understand English
Exclusion Criteria:
- Have a diagnosed autoimmune or inflammatory disease
- Have had a cancer diagnosis and/or treatment within the last 5 years
- Have diagnosed type 1 or 2 diabetes
- Have a history of cardiovascular events (e.g., heart attack, stroke)
- Are taking glucose-lowering or thyroid medications
- Are currently taking ketone supplements, practice intermittent fasting, following a ketogenic diet, or are actively trying to lose or gain weight (more than 4 kg weight loss or gain in the last month)
- Are accumulating 150 minutes or more of moderate-to-vigorous physical activity per week, or are participating in moderate-to-vigorous physical activity on 3 or more days per week
- Smoke cigarettes or cannot refrain from smoking/using cannabis for the duration of the study
- Are currently pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Obese
Individuals with obesity will be recruited.
Obesity will be defined as having a body mass index >= 30 kg/m2 or a waist circumference of > 88cm (females) or >102 cm (males).
|
Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
|
|
Active Comparator: Lean
Lean individuals will be recruited and will act as the reference arm such that we will compare responses of individuals with obesity to the lean group.
This group will be defined as having a BMI between 18.5-24.9
kg/m2 and a waist circumference of less than 88 cm (females) or 102 cm (males)
|
Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the rate of T cell fat-supported oxidative mitochondrial respiration assessed by Oroboros O2K after 48 hours of fasting
Time Frame: Baseline and 48 hours
|
T cell respiration will be characterized in inactivated and activated T cells collected at baseline and after 48 hours of fasting.
Inactivated T cells will be assessed immediately following isolation.
Activated T cells will be assessed after culturing with CD3/CD28 for 24 hours.
|
Baseline and 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in the frequency (%) of T cell subsets assessed by multi-colour flow cytometry
Time Frame: Baseline and 48 hours
|
Isolated T cells collected at baseline and after 48 hours of fasting will be cultured with CD3/CD28 for 24 hours after which their phenotype will be assessed to determine the frequency (%) of the major T cell subsets.
The T cell subsets that will be characterized are T regulatory cells, subsets of T helper cells (Th1, Th2, Th17, Th22), and subsets of cytotoxic T cells (Tc1, Tc2, Tc17, and Tc22).
|
Baseline and 48 hours
|
|
Change from baseline in the rate of T cell proliferation assessed by cell number
Time Frame: Baseline and 48 hours
|
Isolated T cells collected at baseline and after 48 hours of fasting will be cultured with CD3/CD28 for 72 hours.
The rate of cell proliferation after 72 hours is indicative of T regulatory cell suppressor function.
|
Baseline and 48 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H22-03605
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
University of ÉvoraNot yet recruitingObesity and Obesity-related Medical Conditions
-
The Hospital for Sick ChildrenCompleted
Clinical Trials on Fasting
-
Kasr El Aini HospitalCompleted
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Cairo UniversityWithdrawnPolycystic Ovary Syndrome | InfertilityEgypt
-
Shiraz University of Medical SciencesCompletedCoronary Artery DiseaseIran, Islamic Republic of
-
Charite University, Berlin, GermanyCompletedCancer | Fasting | NeoplasiaGermany
-
University of British ColumbiaRecruitingGlucose Tolerance | Fasting | Immune FunctionCanada
-
HealthPartners InstituteCompletedDiabetes Mellitus | Hyperlipidemia | Normal Glucose MetabolismUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Universidade de Passo FundoFederal University of Rio Grande do SulCompleted